Vanguard Global Advisers
AKTS

Vanguard Global Advisers’s Aktis Oncology AKTS Stock Holding History

Vanguard Global Advisers’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
6,886
-2,803
-29% -$57.6K ﹤0.01% 2461
2026
Q1 		$173K Buy
+9,689
New +$188K ﹤0.01% 2504

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Global Advisers's AKTS Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Aktis Oncology (AKTS) stake by 29% in Q2 2026, selling an estimated $57.6K and leaving 6,886 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #2461.

Vanguard Global Advisers first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • Vanguard Global Advisers held 6,886 shares of Aktis Oncology worth $222K as of Q2 2026.
  • Vanguard Global Advisers sold 2,803 Aktis Oncology shares in Q2 2026, an estimated $57.6K.
  • Aktis Oncology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2461 holding.
  • Vanguard Global Advisers first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.